Good news! Vaccine is relatively cheap, easy to produce & store, well tolerated. 3B doses projected in 2021
Haven't seen submission or decision, but MHRA reportedly approved 2 dose regimen (62% effective) & is encouraging a 1-dose regimen to speed access
Haven't seen submission or decision, but MHRA reportedly approved 2 dose regimen (62% effective) & is encouraging a 1-dose regimen to speed access
https://twitter.com/MaxCRoser/status/1344181829029474304?s=20
Results published in Lancet indicate say this a/b 1 dose regimen
It will be interesting to see public response and distribution strategy for regimen w/lower efficacy than Pfizer/Moderna options & uncertainty about duration of protection
thelancet.com/journals/lance…
It will be interesting to see public response and distribution strategy for regimen w/lower efficacy than Pfizer/Moderna options & uncertainty about duration of protection
thelancet.com/journals/lance…
Apparently, Oxford/AstraZeneca has not even filed a submission package with EMA yet. FDA decision isn't coming soon either.
This is such an important vaccine for global access and so much is strange about how its sponsors have pursued it
reuters.com/article/us-hea…
This is such an important vaccine for global access and so much is strange about how its sponsors have pursued it
reuters.com/article/us-hea…
Here is the statement on the MHRA approval.
Interestingly, the advice on the single-dose regimen comes from Joint Committee on Vaccination and Immunisation (JCVI), which is co-chaired by Andrew Pollard, Director of Oxford Vaccine Group
gov.uk/government/new…
Interestingly, the advice on the single-dose regimen comes from Joint Committee on Vaccination and Immunisation (JCVI), which is co-chaired by Andrew Pollard, Director of Oxford Vaccine Group
gov.uk/government/new…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
